Hepatitis

Abnormal Bone Metabolism With Tenofovir for HBV Infection

Abnormal Bone Metabolism With Tenofovir for HBV Infection

By

Long-term treatment with tenofovir for hepatitis B virus infection is associated with hypophosphatemia and elevated serum levels of fibroblast growth factor 23, a hormone that induces renal phosphate excretion.

Clinical Guideline on Evaluating Abnormal Liver Chemistries

Clinical Guideline on Evaluating Abnormal Liver Chemistries

By

The American College of Gastroenterology released a set of guideline for evaluating abnormal liver chemistries.

FDA Expands Indication, Adds Boxed Warning for HCV Drug

FDA Expands Indication, Adds Boxed Warning for HCV Drug

By

FDA expanded indication for Technivie (ombitasvir, paritaprevir, ritonavir; AbbVie) and added a boxed warning for treatment of patients with HCV infection with compensated cirrhosis.

Low Rates of HCV Testing Seen in Baby Boomers

Low Rates of HCV Testing Seen in Baby Boomers

Of 76.2 million baby boomers in the US in 2015, only 10.5 million had been tested for hepatitis C, according to new research.

Facilitating Care for Patients With Early Stage Hepatocellular Carcinoma

Facilitating Care for Patients With Early Stage Hepatocellular Carcinoma

By

Investigators proposed an algorithm to facilitate the decision-making process of clinical care for patients with very early hepatocellular carcinoma.

Anti-HBs Protect Against HBV Reactivation During Chemotherapy

Anti-HBs Protect Against HBV Reactivation During Chemotherapy

By

Meta-analysis provides further support to findings that show a protective role of antibody to hepatitis B surface antigen against reactivation in patients with resolved HBV undergoing chemotherapy for hematologic tumors without antiviral prophylaxis.

Liver Cancer Rates With Interferon-Free Regimens in HIV/HCV

Liver Cancer Rates With Interferon-Free Regimens in HIV/HCV

By

The incidence of hepatocellular carcinoma after sustained virological response has not increased with the widespread use of all oral direct antivirals regimens as suggested in previous studies, according to a new study.

French Study Points to Eradication of HIV-HCV Coinfection

French Study Points to Eradication of HIV-HCV Coinfection

By

Prevalence of active HIV-HCV coinfection may decrease to 1.1% in France over the next decade.

Antivirals Effective in Patients With HCV Infection and Hemophilia

Antivirals Effective in Patients With HCV Infection and Hemophilia

By

A phase 2b trial showed that direct-acting antivirals were effective for treating hepatitis C virus infection in patients with inherited bleeding disorders.

Liver and Treatment Failure Cases Linked With Newer HCV Antivirals

Liver and Treatment Failure Cases Linked With Newer HCV Antivirals

By

While direct-acting antivirals represent an important advance in the treatment of hepatitis C virus infection, further investigation is needed to understand the reasons for the cases of liver failure and antiviral failure reported to the FDA.

HCV Infection Linked to Nonhepatic Cancers in the Elderly

HCV Infection Linked to Nonhepatic Cancers in the Elderly

By

In the elderly population, hepatitis C virus infection is associated with cancers other than hepatocellular carcinoma, such as bile duct and pancreatic cancers and diffuse large B-cell lymphoma.

Neuropsychiatric Impairment in Patients With HCV Despite Virus Clearance

Neuropsychiatric Impairment in Patients With HCV Despite Virus Clearance

By

Neuropsychiatric syndrome not linked to virus in hepatitis C infection.

Targeted CBT for HCV Patients Helps to Reduce Pain and Substance Use

Targeted CBT for HCV Patients Helps to Reduce Pain and Substance Use

By

Customized CBT reduced substance use disorder, pain severity, and pain interference in veterans with HCV.

Short-Course Tocilizumab May Increase HBV Reactivation in RA

Short-Course Tocilizumab May Increase HBV Reactivation in RA

Three-dose tocilizumab combined with csDMARDs might increase the risk of HBV reactivation in RA patients with chronic HBV infection.

FDA Grants Priority Review to Fixed-Dose Pan-Genotypic HCV Regimen

FDA Grants Priority Review to Fixed-Dose Pan-Genotypic HCV Regimen

By

Priority Review granted to the NDA of glecaprevir/pibrentasvir (G/P; AbbVie) for the treatment of genotypes 1-6 chronic hepatitis C virus infection.

Telemedicine Improves Hepatitis C Treatment Rates in Rural Areas

Telemedicine Improves Hepatitis C Treatment Rates in Rural Areas

By

Using telemedicine consults with specialists to support PCPs enhanced the treatment rates in hepatitis C in rural areas.

Reducing Diabetes Risk Key to Eradicating HCV in Coinfected Patients

Reducing Diabetes Risk Key to Eradicating HCV in Coinfected Patients

Sustained viral response correlated with a significant decrease in the risk of diabetes mellitus and a trend towards decrease in chronic renal failure, according to a study.

Prophylactic Lamivudine Reduces HBV Flares During Chemotherapy

Prophylactic Lamivudine Reduces HBV Flares During Chemotherapy

By

Patients with breast cancer who have chronic HBV infection have fewer flares while undergoing chemotherapy if they are treated with prophylactic lamivudine.

Short-Duration Triple DAA for Chronic HCV With Portal Hypertension

Short-Duration Triple DAA for Chronic HCV With Portal Hypertension

By

Trial finds the combination of simeprevir, daclatasvir, and sofosbuvir generally safe and well tolerated in HCV patients with decompensated liver disease.

First HBV Quantitative Test to Assess Antiviral Therapy Response

First HBV Quantitative Test to Assess Antiviral Therapy Response

By

The new HBV test service from Quest Diagnostics measures the quantity of viral antigen to determine if the immune system is responding to treatment.

Effectiveness of Sorafenib Dependent on Hepatitis Status in HCC

Effectiveness of Sorafenib Dependent on Hepatitis Status in HCC

Meta-analysis shows consistent evidence that in advanced unresectable hepatocellular carcinoma, the effect of sorafenib on overall survival is dependent on patients' hepatitis status.

Liver- and Non-Liver Related Critical Events Down in HCV and Cirrhosis

Liver- and Non-Liver Related Critical Events Down in HCV and Cirrhosis

Researchers found that 50.5% of the patients achieved sustained viral response, which correlated with reduced incidence of hepatocellular carcinoma and hepatic decompensation.

HCV Antivirals Produce Durable Responses Despite Time to Suppression

HCV Antivirals Produce Durable Responses Despite Time to Suppression

By

Newer combinations of HCV genotype 1b antivirals showed sustained virologic response independent of time to viral suppression.

Higher Prevalence of Chronic HBV in Patients With Type 2 Diabetes

Higher Prevalence of Chronic HBV in Patients With Type 2 Diabetes

Researchers found that patients with type 2 diabetes had higher prevalence of chronic hepatitis B virus infection than the controls in the overall population.

Ledipasvir-Sofosbuvir Effective in Treating Adolescents With HCV GT1

Ledipasvir-Sofosbuvir Effective in Treating Adolescents With HCV GT1

Phase 2 multi-center study examined the efficacy and safety of ledipasvir-sofosbuvir in 100 adolescents with chronic HCV genotype 1 infection.

Abbvie Submits New Drug Application to FDA for All Major HCV Genotypes

Abbvie Submits New Drug Application to FDA for All Major HCV Genotypes

By

NDA submitted to the FDA by AbbVie for its investigational regimen of glecaprevir/pibrentasvir to treat all major genotypes of chronic HCV.

Diabetes Increases Risk of Hepatocellular Carcinoma in HCV Patients

Diabetes Increases Risk of Hepatocellular Carcinoma in HCV Patients

Diabetes increased the risk of hepatocellular carcinoma development and all-cause mortality in patients infected with HCV.

WHO Prequalifies First HCV Rapid Diagnostic Test

WHO Prequalifies First HCV Rapid Diagnostic Test

By

The World Health Organization has just prequalified its first hepatitis C virus point-of-care diagnostic test.

FDA: Review Underway for Single Tablet HCV Regimen

FDA: Review Underway for Single Tablet HCV Regimen

By

The once-daily single tablet regimen of sofosbuvir/velpatasvir/voxilaprevir is intended for patients with direct-acting antiviral-experienced hepatitis C infections.

Elevated Risk of HBV Reactivation in Patients With RA

Elevated Risk of HBV Reactivation in Patients With RA

By

In patients with rheumatoid arthritis, low baseline hepatitis B surface antibody titers are significant risk factors for HBV reactivation.

Sign Up for Free e-newsletters